Effects of chronic oral administration of l-deprenyl in the dog
Identifieur interne : 001948 ( Istex/Checkpoint ); précédent : 001947; suivant : 001949Effects of chronic oral administration of l-deprenyl in the dog
Auteurs : N. W Milgram [Canada] ; G. O Ivy [Canada] ; M. P Murphy [Canada] ; E. Head [Canada] ; P. H Wu [Canada] ; W. W Ruehl [Canada] ; P. H Yu [Canada] ; D. A Durden [Canada] ; B. A Davis [Canada] ; A. A Boulton [Canada]Source :
- Pharmacology, Biochemistry and Behavior [ 0091-3057 ] ; 1995.
Abstract
Dogs were administered capsules containing l-deprenyl daily over 3 weeks at dose levels of 0, 0.1, 0.5, and 1.0 mg/kg. Spontaneous behavior was measured using a canine open field test, and was not significantly affected by l-deprenyl. Plasma levels of amphetamine showed a clear dose-dependent elevation 2 h following treatment, but were markedly lower after 24 h, and were undetectable 5 days following the last treatment. Plasma levels of phenylethylamine were increased, but were highly variable. Animals sacrificed 1 day following the last treatment showed a dose-dependent inhibition of monoamine oxidase B in the brain, liver, and kidney, whereas monoamine oxidase A was unaffected in these tissues. l-Deprenyl also caused an increase in phenylethylamine in the striatum and hypothalamus, but not in the neocortex. Brain levels of DA, DOPAC, 3-MT, HVA, 5-HT, and 5-HIAA were unaffected. The pharmacological profile for the dog is distinct from that of other species in that long-term treatment did not produce any significant inhibition of MAO-A activity. The absence of an effect on biogenic amines or metabolites suggests that the metabolism of dopamine is mediated at least in part through pathways other than MAO-B in the normal adult dog.
Url:
DOI: 10.1016/0091-3057(94)00417-H
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
ISTEX:A30110B5198986F739340EB8596571EBF803C2E9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Effects of chronic oral administration of l-deprenyl in the dog</title>
<author><name sortKey="Milgram, N W" sort="Milgram, N W" uniqKey="Milgram N" first="N. W" last="Milgram">N. W Milgram</name>
</author>
<author><name sortKey="Ivy, G O" sort="Ivy, G O" uniqKey="Ivy G" first="G. O" last="Ivy">G. O Ivy</name>
</author>
<author><name sortKey="Murphy, M P" sort="Murphy, M P" uniqKey="Murphy M" first="M. P" last="Murphy">M. P Murphy</name>
</author>
<author><name sortKey="Head, E" sort="Head, E" uniqKey="Head E" first="E" last="Head">E. Head</name>
</author>
<author><name sortKey="Wu, P H" sort="Wu, P H" uniqKey="Wu P" first="P. H" last="Wu">P. H Wu</name>
</author>
<author><name sortKey="Ruehl, W W" sort="Ruehl, W W" uniqKey="Ruehl W" first="W. W" last="Ruehl">W. W Ruehl</name>
</author>
<author><name sortKey="Yu, P H" sort="Yu, P H" uniqKey="Yu P" first="P. H" last="Yu">P. H Yu</name>
</author>
<author><name sortKey="Durden, D A" sort="Durden, D A" uniqKey="Durden D" first="D. A" last="Durden">D. A Durden</name>
</author>
<author><name sortKey="Davis, B A" sort="Davis, B A" uniqKey="Davis B" first="B. A" last="Davis">B. A Davis</name>
</author>
<author><name sortKey="Boulton, A A" sort="Boulton, A A" uniqKey="Boulton A" first="A. A" last="Boulton">A. A Boulton</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:A30110B5198986F739340EB8596571EBF803C2E9</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1016/0091-3057(94)00417-H</idno>
<idno type="url">https://api-v5.istex.fr/document/A30110B5198986F739340EB8596571EBF803C2E9/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002214</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002214</idno>
<idno type="wicri:Area/Istex/Curation">002214</idno>
<idno type="wicri:Area/Istex/Checkpoint">001948</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001948</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Effects of chronic oral administration of l-deprenyl in the dog</title>
<author><name sortKey="Milgram, N W" sort="Milgram, N W" uniqKey="Milgram N" first="N. W" last="Milgram">N. W Milgram</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Life Sciences Division, Scarborough Campus, University of Toronto, Scarborough</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ivy, G O" sort="Ivy, G O" uniqKey="Ivy G" first="G. O" last="Ivy">G. O Ivy</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Life Sciences Division, Scarborough Campus, University of Toronto, Scarborough</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Murphy, M P" sort="Murphy, M P" uniqKey="Murphy M" first="M. P" last="Murphy">M. P Murphy</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Life Sciences Division, Scarborough Campus, University of Toronto, Scarborough</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Head, E" sort="Head, E" uniqKey="Head E" first="E" last="Head">E. Head</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Life Sciences Division, Scarborough Campus, University of Toronto, Scarborough</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Wu, P H" sort="Wu, P H" uniqKey="Wu P" first="P. H" last="Wu">P. H Wu</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Pharmacology, University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ruehl, W W" sort="Ruehl, W W" uniqKey="Ruehl W" first="W. W" last="Ruehl">W. W Ruehl</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Deprenyl Animal Health Inc., Overland Park</wicri:regionArea>
<wicri:noRegion>Overland Park</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yu, P H" sort="Yu, P H" uniqKey="Yu P" first="P. H" last="Yu">P. H Yu</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neuropsychiatric Research, Department of Psychiatry, University of Saskatchewan, Saskatoon</wicri:regionArea>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Durden, D A" sort="Durden, D A" uniqKey="Durden D" first="D. A" last="Durden">D. A Durden</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neuropsychiatric Research, Department of Psychiatry, University of Saskatchewan, Saskatoon</wicri:regionArea>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Davis, B A" sort="Davis, B A" uniqKey="Davis B" first="B. A" last="Davis">B. A Davis</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neuropsychiatric Research, Department of Psychiatry, University of Saskatchewan, Saskatoon</wicri:regionArea>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Boulton, A A" sort="Boulton, A A" uniqKey="Boulton A" first="A. A" last="Boulton">A. A Boulton</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Neuropsychiatric Research, Department of Psychiatry, University of Saskatchewan, Saskatoon</wicri:regionArea>
<wicri:noRegion>Saskatoon</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Pharmacology, Biochemistry and Behavior</title>
<title level="j" type="abbrev">PBB</title>
<idno type="ISSN">0091-3057</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1995">1995</date>
<biblScope unit="volume">51</biblScope>
<biblScope unit="issue">2–3</biblScope>
<biblScope unit="page" from="421">421</biblScope>
<biblScope unit="page" to="428">428</biblScope>
</imprint>
<idno type="ISSN">0091-3057</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0091-3057</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Dogs were administered capsules containing l-deprenyl daily over 3 weeks at dose levels of 0, 0.1, 0.5, and 1.0 mg/kg. Spontaneous behavior was measured using a canine open field test, and was not significantly affected by l-deprenyl. Plasma levels of amphetamine showed a clear dose-dependent elevation 2 h following treatment, but were markedly lower after 24 h, and were undetectable 5 days following the last treatment. Plasma levels of phenylethylamine were increased, but were highly variable. Animals sacrificed 1 day following the last treatment showed a dose-dependent inhibition of monoamine oxidase B in the brain, liver, and kidney, whereas monoamine oxidase A was unaffected in these tissues. l-Deprenyl also caused an increase in phenylethylamine in the striatum and hypothalamus, but not in the neocortex. Brain levels of DA, DOPAC, 3-MT, HVA, 5-HT, and 5-HIAA were unaffected. The pharmacological profile for the dog is distinct from that of other species in that long-term treatment did not produce any significant inhibition of MAO-A activity. The absence of an effect on biogenic amines or metabolites suggests that the metabolism of dopamine is mediated at least in part through pathways other than MAO-B in the normal adult dog.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
<region><li>Ontario</li>
</region>
<settlement><li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Ontario"><name sortKey="Milgram, N W" sort="Milgram, N W" uniqKey="Milgram N" first="N. W" last="Milgram">N. W Milgram</name>
</region>
<name sortKey="Boulton, A A" sort="Boulton, A A" uniqKey="Boulton A" first="A. A" last="Boulton">A. A Boulton</name>
<name sortKey="Davis, B A" sort="Davis, B A" uniqKey="Davis B" first="B. A" last="Davis">B. A Davis</name>
<name sortKey="Durden, D A" sort="Durden, D A" uniqKey="Durden D" first="D. A" last="Durden">D. A Durden</name>
<name sortKey="Head, E" sort="Head, E" uniqKey="Head E" first="E" last="Head">E. Head</name>
<name sortKey="Ivy, G O" sort="Ivy, G O" uniqKey="Ivy G" first="G. O" last="Ivy">G. O Ivy</name>
<name sortKey="Murphy, M P" sort="Murphy, M P" uniqKey="Murphy M" first="M. P" last="Murphy">M. P Murphy</name>
<name sortKey="Ruehl, W W" sort="Ruehl, W W" uniqKey="Ruehl W" first="W. W" last="Ruehl">W. W Ruehl</name>
<name sortKey="Wu, P H" sort="Wu, P H" uniqKey="Wu P" first="P. H" last="Wu">P. H Wu</name>
<name sortKey="Yu, P H" sort="Yu, P H" uniqKey="Yu P" first="P. H" last="Yu">P. H Yu</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001948 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 001948 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Istex |étape= Checkpoint |type= RBID |clé= ISTEX:A30110B5198986F739340EB8596571EBF803C2E9 |texte= Effects of chronic oral administration of l-deprenyl in the dog }}
This area was generated with Dilib version V0.6.29. |